Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIMALAYA: first-line durvalumab and tremelimumab versus sorafenib in advanced hepatocellular carcinoma
CTR20180607Phase 3Active
- Sponsor
- MedImmune
- Start
- Nov 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab, tremelimumab in hepatocellular carcinoma (HCC), sponsored by MedImmune. Started Nov 2020; status: active.
02
Drugs
durvalumabtremelimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20180607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180607.